Literature DB >> 17276950

Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.

Koji Arihiro1, Shinobu Umemura, Masafumi Kurosumi, Takuya Moriya, Tetsunari Oyama, Hiroko Yamashita, Yoshihisa Umekita, Yoshifumi Komoike, Chikako Shimizu, Hisaki Fukushima, Hiroshi Kajiwara, Futoshi Akiyama.   

Abstract

The aims of this study were to compare the quality of immunohistochemical assays of estrogen receptor (ER) and progesterone receptor (PR) and to compare the intermethod variability of assays from different manufacturers. immunohistochemical staining was entrusted to the following laboratories in Japan: Kyowa Medex, dealing with the products of BioGenex (Mishima, Shizuoka), DAKO Japan (Kyoto) and Ventana Japan (Yokohama). All slides were semiquantitatively evaluated according to the Allred score. Intermethod variability showed fair to moderate multirater kappa values for ER and PR (for total score, ER, kappa = 0.34; PR, kappa = 0.45). Another scoring system was also applied in which, irrespective of the intensity of nuclear staining, the proportion of cells stained in each specimen was recorded as 0; less than 1%; 1% or more and less than 10%; or 10% or more. Intermethod variability showed substantial multirater kappa values for ER and PR (according to percentage of positive cells, ER, kappa = 0.67; PR, kappa = 0.72). Concerning intermethod consistency, the scoring system based on the percentage of positive cells was advantageous over other scoring systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276950     DOI: 10.1309/4D1A04NCDK96WFY7

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

Review 1.  Practical implications of gene-expression-based assays for breast oncologists.

Authors:  Aleix Prat; Matthew J Ellis; Charles M Perou
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Comparison of evaluations of hormone receptors in breast carcinoma by image-analysis using three automated immunohistochemical stainings.

Authors:  Koji Arihiro; Miyo Oda; Katsunari Ogawa; Kenshi Tominaga; Yoshie Kaneko; Tomomi Shimizu; Shiho Ohnishi; Megumi Oda; Yuki Kurita; Yuko Taira; Masayoshi Fujii; Maiko Tanaka
Journal:  Exp Ther Med       Date:  2010-08-26       Impact factor: 2.447

3.  Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans of the rat liver.

Authors:  Yuko Nakamura; Yutaka Hirokawa; Shigemi Kitamura; Wataru Yamasaki; Koji Arihiro; Fuminari Tatsugami; Makoto Iida; Hideaki Kakizawa; Shuji Date; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2013-04-19       Impact factor: 2.374

4.  An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

Authors:  Jelle Wesseling; Corrado Tinterri; Anna Sapino; Fabrizio Zanconati; Martijn Lutke-Holzik; Bichlien Nguyen; Kenneth B Deck; Patrizia Querzoli; Tiziana Perin; Carmela Giardina; Gerhard Seitz; Jean-Marc Guinebretière; Julie Barone; Laura Dekker; Femke de Snoo; Lisette Stork-Sloots; Paul Roepman; Toru Watanabe; Pino Cusumano
Journal:  Virchows Arch       Date:  2016-07-04       Impact factor: 4.064

5.  Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years.

Authors:  Anas M Alsughayer; Tamara Z Dabbagh; Rashid H Abdel-Razeq; Ghada N Al-Jussani; Salam Alhassoon; Maher A Sughayer
Journal:  JCO Glob Oncol       Date:  2022-03

6.  Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer.

Authors:  Sas Leen; Van Laere Steven; Dierick Anne Marie; Duwel Valérie; De Pauw Annemie; Van Den Eynden Gert; Van Dam Peter; Dirix Luc; Vermeulen Peter; Lardon Filip
Journal:  Patholog Res Int       Date:  2014-03-06

7.  Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Authors:  D Mouttet; M Laé; M Caly; D Gentien; S Carpentier; H Peyro-Saint-Paul; A Vincent-Salomon; R Rouzier; B Sigal-Zafrani; X Sastre-Garau; F Reyal
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

8.  Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays.

Authors:  Shazia Akbar; Lee B Jordan; Colin A Purdie; Alastair M Thompson; Stephen J McKenna
Journal:  Br J Cancer       Date:  2015-09-08       Impact factor: 7.640

9.  Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon.

Authors:  Ghina B Fakhri; Reem S Akel; Maya K Khalil; Deborah A Mukherji; Fouad I Boulos; Arafat H Tfayli
Journal:  Int J Breast Cancer       Date:  2018-05-31

10.  A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy.

Authors:  Yanhua Chen; Hao Cai; Wannan Chen; Qingzhou Guan; Jun He; Zheng Guo; Jing Li
Journal:  Front Mol Biosci       Date:  2020-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.